2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

401. Blood Transfusion: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Serologic Tests, Blood Banking, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Immunology, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3114 A real-world multi-center retrospective analysis on mortality rates from a restrictive versus liberal transfusion strategy in patients with active hematological malignancies

Richard Wu, MD, Taylor Barrow, MD2
1 Boston Medical Center, Boston, United States
2 Boston Medical Center, Boston, United States

Background: Anemia is a common complication of hematological malignancies as a result of direct complications from the cancer itself, as well as the therapies that treat it. Transfusions of red blood cells is a common supportive therapy that many patients with hematological malignancies will undergo to improve quality of life and mortality. However, regular transfusions are not without harm due to risks of high risk transfusion reactions, fluid shifts, antigen exposure, and infections. In the general population, research has increasingly shown that restricting transfusion to only patients with severe anemia as defined by hemoglobins less than 7 g/dL is safe. Unfortunately, evidence remains lacking on whether this same threshold is appropriate for patients with hematologic malignancies. Moreover, concurrent thrombocytopenia, a common problem in malignant conditions, confers a risk of bleeding that is significantly augmented by worsening levels of anemia, and is a risk that is often unique to oncologic patients.

Methods: We conducted a real-world retrospective cohort study utilizing the TriNetX Research Network database, a multicenter federated electronic health record platform including de-identified data from 112 healthcare organizations. Adults aged 18 years or older with a diagnosis of multiple myeloma, Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, acute promyelocytic anemia, or acute myelomonocytic leukemia between January 1st, 2000 to January 1st, 2026, who initiated oncologic therapy within four weeks of diagnosis, and who subsequently received a blood transfusion within four weeks of diagnosis were eligible for inclusion. The restrictive transfusion cohort was defined by patients who only received transfusions of red blood cells for hemoglobins of ≤ 7 g/dL, and the liberal transfusion cohort was composed of patients who received transfusions for hemoglobins between 8 to 12 g/dL inclusive. Patients who died within four weeks of the index malignancy diagnosis were excluded and a landmark time of week four was set for analysis. Baseline characteristics were ascertained from the 180 days prior to the index day of malignancy diagnosis. Propensity matching was conducted using 1:1 greedy nearest-neighbor matching based on demographic and laboratory data, type of malignancy, chronic comorbidities drawing from diagnoses found in the Charlson Comorbidity Index and the Acute Myeloid Leukemia Composite Model, bone marrow suppression, utilization of erythropoietin stimulating agents, and antiplatelet/anticoagulant use. The primary outcome of interest is mortality at one year and the secondary outcome evaluated was the need for additional blood transfusions.

Results: 3,258 patients in the liberal cohort and 272 in the restrictive cohort met criteria for inclusion. After propensity matching, 237 patients remained in each cohort. A restrictive transfusion strategy was associated with a significantly higher mortality at one year (HR 1.97, 95% CI 1.35 - 2.86; p = 0.0003) but with a significantly lower likelihood of transfusion (HR 0.68, 95% CI 0.50 - 0.92; p - 0.0122) and significantly less blood transfusions overall when compared to their liberal transfusion counterparts (mean 1.62, standard deviation 6.2 for restrictive; mean 3.5, standard deviation 7.9 for liberal; p = 0.0037).

Conclusion: This large, multicenter retrospective real-world study pulls from the largest population that we are aware of and highlights a signal for increased mortality and decreased utilization of red blood cell transfusions in patients with hematological malignancies that were transfused under a restrictive strategy, as defined by transfusing only for hemoglobin levels < 7 g/dL, compared with a liberal strategy where transfusions occurred for hemoglobin levels between 8 to 12 g/dL. Despite significant efforts at matching patients for severity of illness, the results here should be interpreted with caution as the retrospective nature of the data makes residual confounding due to severity of malignancy a potential source of bias. This should be rectified with further prospective studies to better delineate an optimal transfusion threshold for patients with active hematological malignancies and anemia. 

Taylor Barrow, MD: No relevant conflicts of interest to declare.